event-free survival

event-free survival

Failure-free survival Oncology The timespan that follows therapy for a malignancy or other dread disease, during which there are no objective signs of recurrence
References in periodicals archive ?
Previously published natural history data indicate that in a comparable historic cohort the median age of event-free survival for SMA Type 1 infants to be between 8 and 10.
The primary endpoint was event-free survival (EFS).
Event-free survival was significantly higher for patients receiving RYDAPT plus chemotherapy versus chemotherapy alone a median of 8.
The global rank composite scores were derived based on a hierarchy of outcomes including--in rank order death, event-free survival, forced vital capacity, scleroderma health assessment questionnaire score, and modified Rodnan skin score (mRSS); each patient was compared, based on the hierarchy, with every other patient in the study.
In Kaplan–Meier analysis, the group with hs-CRP >3 mg/L had a lower cumulative 66-month event-free survival rate (log-rank test for trend, P = 0.
Patients with high quartile of red blood cell glutathione peroxidase activity were the ones most likely to have event-free survival during a 5-plus year follow-up, according to a 2003 New England Journal of Medicine study led by S.
The second objective was to retrospectively determine the clinically significant prostate-related event-free survival of patients undergoing RP at a population level in British Columbia (BC).
Event-free survival (EFS) was defined as the time from study enrollment to the first occurrence of progression, relapse after response, or death from any cause.
The European approval was based on demonstration of improved event-free survival and overall survival in a multicentre, open-label, randomised trial sponsored by the US National Cancer Institute under a Cooperative Research and Development Agreement with United Therapeutics and conducted by the Children's Oncology Group.
For patients with localised disease at presentation 3-year event-free survival was 30% and 3-year overall survival was 71%.
The study was halted early for futility after a median follow-up of 48 months because of virtually identical event-free survival rates in the two study arms.
In contrast, cumulative event-free survival rates for hard cardiac events and all cardiac events were 78% and 56% in patients with nonobstructive CAD, and 60% and 16% in those with obstructive CAD (P = .